Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

nintedanib

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Multi-tyrosine kinase inhibitor

Related drugs:

No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	nintedanib Sensitive: A1 - Approval nintedanib Sensitive : A1	nintedanib Sensitive: A1 - Approval nintedanib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C2 – Inclusion Criteria nintedanib Sensitive : C2	nintedanib Sensitive: C2 – Inclusion Criteria nintedanib Sensitive : C2
miR-34a-5p underexpression	Ovarian Cancer	miR-34a-5p underexpression	Ovarian Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
TP53 mutation	Non Small Cell Lung Cancer	TP53 mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
PDGFRA mutation	Non Small Cell Lung Cancer	PDGFRA mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
FGFR1 mutation	Non Small Cell Lung Cancer	FGFR1 mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
FGFR2 mutation	Non Small Cell Lung Cancer	FGFR2 mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
FGFR3 mutation	Non Small Cell Lung Cancer	FGFR3 mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
FLT1 mutation	Non Small Cell Lung Cancer	FLT1 mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
FLT3 mutation	Non Small Cell Lung Cancer	FLT3 mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
PDGFRB mutation	Non Small Cell Lung Cancer	PDGFRB mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
KDR mutation	Non Small Cell Lung Cancer	KDR mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
KIF5B-RET fusion	Non Small Cell Lung Cancer	KIF5B-RET fusion	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
PAX5 fusion	Childhood B Acute Lymphoblastic Leukemia	PAX5 fusion	Childhood B Acute Lymphoblastic Leukemia	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
PD-L1 overexpression	Mesothelioma	PD-L1 overexpression	Mesothelioma	pembrolizumab + nintedanib Sensitive: C3 – Early Trials pembrolizumab + nintedanib Sensitive : C3	pembrolizumab + nintedanib Sensitive: C3 – Early Trials pembrolizumab + nintedanib Sensitive : C3
FGFR mutation	Squamous Cell Carcinoma of Head and Neck	FGFR mutation	Squamous Cell Carcinoma of Head and Neck	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
FGFR2 amplification	Gastric Adenocarcinoma	FGFR2 amplification	Gastric Adenocarcinoma	nintedanib Sensitive: D – Preclinical nintedanib Sensitive : D	nintedanib Sensitive: D – Preclinical nintedanib Sensitive : D